Is this you?
Request access for DelRicht Research with your @delrichtresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
DelRicht Research
Unclaimed profileSite Network · New Orleans, Louisiana · ~33 sites
Intera lens
ICP 8Lift (cardio sample) 0.18Recruit soph 0.57
Quality Scorecard (1–100)
Overall69Recruit76Ops64Sponsor72Ther64
Performance (observed)
Historical trials
201
Completed
115
Terminated/Withdrawn
20
Completion rate
85%
Active now
64
Phase 2
77
Phase 3
116
Realized enrollment
320,182
First study year
2016
Years active
10
Match confidence
high
Enrollment velocity (inf)
32,018
Therapeutic
Areas
General Medicine, Dermatology, Psychiatry, Neurology, Cardiolometabolic, Ophthalmology, Allergy/ENT/Respiratory, Vaccine, Rheumatology, Urology
Breadth (conditions)
163
Languages
English + Spanish (detected)
States
AR, CO, GA, IN, KS, KY, LA, MD, MO, MS, NC, OH, OK, SC, TN, TX, VA (18 states)
Recruitment (web observed)
Meta Pixel
Yes
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
Capability notes
450+ trials since 2014; 15k+ patients enrolled; 96% of trials meet or exceed enrollment; embedded model with dedicated research staff in physician practices
Relationships
Sponsors
AbbVie; Pfizer; Incyte Corporation; ModernaTX, Inc.; Eli Lilly and Company; Biohaven Therapeutics Ltd.
CROs
Abond CRO Inc.; Allucent (US) LLC; Ergomed PLC; ICON Clinical Research; ICON plc; Parexel
Owner / parent
Tyler Hastings (Managing Partner/Founder, 2014)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Riley Kammer (VP Business Development)
Emails
info@delricht.com
Tech & DCT
Builds tech
Unknown
Tech stack
Unknown
Recruiting visible
Y
Notes
Strong fit: 33 sites across 18 states, diverse therapeutic areas, high enrollment performance (96% meet/exceed targets), embedded physician model enables scale, active recruitment advertising, publicly visible studies. Founded 2014 with strong growth trajectory. Slightly lower score due to lack of visible tech stack/AI innovation mentioned. [Validated: 4 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 0.42Liftability 0.18Overall69
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.